Proximal hereditary spinal muscular atrophy (SMA) is caused by homozygous deletion or mutation in the survival motor neuron 1 (*SMN1*) gene, combined with the presence of a variable number of copies of a related gene, *SMN2*.^[@R1]^ SMA has a striking spectrum of severity, ranging from severe antenatal to mild adult onset motor deficits. This variation is reflected by the widely used classification system that distinguishes types 0/1a - 4, based on the age at onset and the higher of 2 acquired motor milestones (e.g., sitting and walking independently).^[@R2]^

The backup *SMN2* gene determines residual SMN protein levels in cells.^[@R3],[@R9],[@R41]^ The SMN protein has multiple functions, including messenger RNA (mRNA) and ubiquitin homeostasis,^[@R4],[@R5]^ axonal transport,^[@R6],[@R7]^ and endocytosis.^[@R8]^ Differences in SMA severity are primarily explained by variation in copy numbers of *SMN2*, but still 20%--40% of the clinical variability does not correspond with the *SMN2* copy number.^[@R9],[@R10]^ *SMN2* point mutations, in particular c.859G\>C,^[@R11]^ and possible epigenetic variation^[@R12]^ have been identified as additional severity modifying factors by changing amino acids, disrupting exonic splice enhancer (ESE) or exonic splice silencer (ESS), or altering expression of SMN in other ways. However, none of these intragenic *SMN2* modifiers explain the full range of severity in SMA. It is therefore likely that there are additional modifiers of disease severity outside the *SMN2* gene.^[@R10],[@R13]^ Candidates include genes encoding proteins that interact with SMN in complexes or that have been shown to rescue SMN-dependent downstream cellular functions. For example, mutations in fused in sarcoma (*FUS*) can disrupt the axonal distribution pattern of SMN and were found to be associated with lower motor neuron syndromes.^[@R14]^ Moreover, transactive response DNA-binding protein 43 (*TDP-43*) is a major constituent of pathologic ubiquitinated protein aggregates in target tissues of patients with sporadic (lower) motor neuron disease.^[@R15],[@R16]^ In addition, profilin 2 (*PFN2*) is important for preservation of cytoskeletal integrity and neuritogenesis.^[@R17],[@R18]^ Of interest, each of these genes has also been implicated in other types of motor neuron disease and therefore provide possible functional links between SMA and other motor neuron diseases.^[@R15],[@R16],[@R19][@R20][@R21]^

The plastin 3 (*PLS3*) gene has been mapped to chromosome Xq23 and encodes an actin-binding protein.^[@R13]^ Although PLS3 probably does not directly interact with SMN, it represents an additional SMA severity modifying candidate gene because its overexpression was found in asymptomatic women with a homozygous *SMN1* deletion who had male relatives with SMA type 3.^[@R13]^ Although the genetic background of PLS3 overexpression in individuals is unclear, PLS3 overexpression in experimental models for SMN deficiency reversed defects in axonogenesis and endocytosis.^[@R8],[@R13],[@R22]^

The incidence and effect of variation in these potential modifying genes in patients with SMA have not yet been explored in detail. Identification of these modifiers will help to dissect cellular processes and pathways that are affected by SMN deficiency and that may represent further therapeutic targets for SMA. We therefore investigated the presence of single nucleotide variants in *PLS3, FUS, TDP-43,* and *PFN2* in a cohort of 153 patients with SMA types 1--4 to explore their potential role as SMA severity modifying genes. We included 19 families, 11 of which had sibs with differing degrees of severity.

Methods {#s1}
=======

We enrolled patients with SMA types 1--4 between September 2010 and August 2014. Methods are described in appendix e-1 ([links.lww.com/NXG/A203](http://links.lww.com/NXG/A203)).

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

The Medical Ethical Committee of the University Medical Center Utrecht approved the study protocol. This study was registered at the Dutch registry for clinical studies and trials ([ccmo-online.nl](http://www.ccmo-online.nl/)).

Data availability {#s1-2}
-----------------

Anonymized data that support the findings of this study are available from the corresponding author on reasonable request.

Results {#s2}
=======

Patients {#s2-1}
--------

We included 153 patients. Characteristics of the participants are summarized in [table 1](#T1){ref-type="table"}.

###### 

Patient characteristics

![](NG2019011015t1)

All but 1 patient had homozygous deletion of at least exon 7 of *SMN1*. One patient had a heterozygous deletion of *SMN1* and a point mutation in exon 4 (c.542A\>G), which created a new splice-donor site within exon 4 of *SMN1* and an out-of-frame transcript (i.e., null allele).

Forty-two patients had a discordant phenotype (16 SMA type 1 with 3 or 4 *SMN2* copies; 8 SMA type 2 with 2 or 4 *SMN2* copies; 21 SMA type 3 with 3 or 5 *SMN2* copies). Two patients with a discordant phenotype of SMA type 2 and only 2 *SMN2* copies harbored the c.859G\>C mutation in *SMN2* exon 7.^[@R11]^

We included 19 families encompassing a total of 35 siblings and first-degree relatives. Eleven (58%) families, including 26 siblings and first-degree cousins, were discordant (e.g., brother with SMA type 3a and sister with SMA type 2b), despite similar *SMN2* copy numbers in 17 of the 19 families (90%).

Variation in sequences of *FUS, PFN2, TDP-43*, and *PLS3* {#s2-2}
---------------------------------------------------------

We identified 2 exonic variants in *FUS,* 8 intronic variants in *PLS3,* 2 intronic variants in *PFN2*, and 1 intronic variant in *TDP-43*. The full list of sequence variations in *FUS, PFN2, PLS3*, and *TDP-43* is provided in the supplementary file (table e-1, [links.lww.com/NXG/A202](http://links.lww.com/NXG/A202)).

Variation in coding sequences of *FUS* {#s2-3}
--------------------------------------

We identified 2 different heterozygous missense sequence variants in *FUS* in 2 unrelated patients ([table 2](#T2){ref-type="table"}) and no intronic variants. One patient carried a mutation in *FUS* exon 6 (c.646C\>T; p.R216C) that is predicted to be damaging (PolyPhen-2 score 0.997; sensitivity 0.41; specificity 0.98). This variant has been reported previously in patients with familial amyotrophic lateral sclerosis (ALS) with a lower motor neuron phenotype^[@R21],[@R23]^ and patients with familial essential tremor.^[@R24]^ This patient has SMA type 1c and has 3 *SMN2* copies. Disease course did not differ from what was expected in SMA type 1c with 3 *SMN2* copies. Age at onset was 4 months, when she lost the ability to lift her head in prone position. She has never acquired the ability to roll over or sit without support. At the time of inclusion, she was aged 13 years and still without respiratory support, despite episodes of pneumonia. This patient had a postural tremor that was not more pronounced than in other patients with SMA types 1c or 2.

###### 

Characteristics of 2 nonrelated patients with exonic variants in *FUS*

![](NG2019011015t2)

We identified another *FUS* variant in exon 5 (c.404G\>A; p.S135N). This *FUS* variant has not been reported before and is predicted to be benign (PolyPhen-2 score 0.004; sensitivity 0.97, specificity 0.59). At the time of inclusion, the patient was aged 19.5 years, and disease course did not differ from what was expected in SMA type 2a. Disease onset was at 6 months, and she carried 3 *SMN2* copies. She started with noninvasive respiratory support at age 12 years. Her elder brother, aged 22.5 years at the time of inclusion, also carried 3 *SMN2* copies but lacked the variant in *FUS.* He had an SMA type 2b phenotype reaching an additional motor milestone, i.e., standing with support, and did not need respiratory support at age 26 years (last follow-up).

Genetic variation in *PFN2* and *TDP-43* {#s2-4}
----------------------------------------

No exonic variants could be confirmed in *PFN2* or *TDP-43*. We identified 3 heterozygous, intronic variants in *PFN2* and *TDP-43* (table e-1, [links.lww.com/NXG/A202](http://links.lww.com/NXG/A202)). The A/C variant in intron 2 of PFN2 is located in an ESS, although none of the variants were predicted to alter splicing (HumanSpliceFinder).

Variation in intronic sequences and expression levels of *PLS3* {#s2-5}
---------------------------------------------------------------

We identified a total of 8 intronic variants in *PLS3* (table e-1, [links.lww.com/NXG/A202](http://links.lww.com/NXG/A202)) but no exonic or coding variants. We found 5 variants in 26 patients, affecting ESS sites (c.748+130G\>A; c.891-25TC (rs145269469); c.1377+17A\>G (rs150802596); c.1511+82T\>C) or creating new ESE sites (c.367+182C\>T; c.1511+82T\>C; c.891-25T\>C (rs145269469)) ([figure 1](#F1){ref-type="fig"}). The c.1511+82T\>C variant occurred in 4 patients, 3 of whom carried a second variant (c.1511+82T\>C and c.367+182C\>T). None of these sites was predicted to have an effect on splicing (HumanSpliceFinder), although the functional effect of each variant on ESS/ESE would remain to be determined. Minor allele frequency was between 0.006 and 0.040 in all variants (Project MinE databrowser, gnomAD, ExAC).

![Reads of variants in *PLS3*\
Results showing reverse reads of Sanger sequencing genomic DNA. (A) Heterozygous variant in intron 3 (c.367+182 C\>T) in a female patient. (B) No variant in sequence of the brother, who has a milder phenotype. (C) Control with wild-type sequence.](NG2019011015f1){#F1}

To analyze potential effects of these variants on PLS3 expression levels, we performed expression analysis in blood of patients for which RNA had been collected. Expression analysis was performed in 50 patients and 21 healthy controls ([table 1](#T1){ref-type="table"}). Healthy controls (median age 68 years \[range 38--78 years\]) included 6 females (29%). Expression levels of PLS3 ranged from 1.4--26.0 copies/ng copyDNA (cDNA) (median 10.6, mean 10.8). Expression levels did not differ between patients and controls (*p* = 0.6; median level in patients: 10.2 copies/ng cDNA \[range 1.7--26.0 copies/ng cDNA\]; median level in controls: 12.2 copies/ng cDNA \[range 1.4--18.0 copies/ng cDNA\]), nor between males and females (controls *p* = 0.8; patients with SMA *p* = 0.9) ([figure 2A](#F2){ref-type="fig"}). In patients, PLS3 expression levels correlated with age in males (n = 24) (Spearman rho −0.44; *p* = 0.03), but not in females (n = 26) (Spearman rho −0.17, *p* = 0.41). There was no correlation between PLS3 levels and the *SMN2* copy number (*p* = 0.32).

![Expression levels of PLS3\
Results showing expression levels of PLS3 and the effects of (A) sex in patients and controls and (B) different intronic variants in the *PLS3* gene. Expression levels of PLS3 are expressed in copies per nanogram cDNA. TBP and HRPT1 were both used as references. Variant status of the included controls is unknown. (A) Sex did not consistently affect expression levels in patients or controls (*p* = 0.5). Expression levels of PLS3 did not differ between patients and controls (*p* = 0.6) or SMA types (*p* = 0.4). (B) Patients are reflected by diamond (male) or bullet (female) with color representing SMA type. Variants in intron 3 (c.367+182C\>T) result in higher levels of PLS3 (*p* = 0.04; median expression levels of PLS3 in patients and controls 10.8 copies per nanogram cDNA (range 1.4--26.0 copies per nanogram cDNA); median expression in intron 3 altered patients 19.1 copies per nanogram cDNA (range 12.1--23.0 copies per nanogram cDNA). Two siblings of a family carrying the c.367+182C\>T variant showed a more severe phenotype (type 2b) in the sibling carrying the variant compared with the sibling who did not carry the variant (type 3a). The expression levels of PLS3 were only available from the sibling with the variant (marked by "X"). Another family carrying this variant included 2 siblings and their cousin, all carrying the same variant, but having different SMA types (type 3a \[siblings\] and type 2a \[cousin\]). The siblings had similar expression levels of PLS3 (marked by "\*"). PLS3 expression level in the cousin was not available. cDNA= copy DNA; SMA = spinal muscular atrophy.](NG2019011015f2){#F2}

Expression levels in patients carrying the variant in intron 3 (c.367+182C\>T) were higher compared with patients not carrying the variant ([figure 2B](#F2){ref-type="fig"}) (*p* = 0.04), possibly indicating a functional effect of this variant as a novel ESE. Other variants were not associated with expression changes. We could not perform expression analysis in patients with the c.1511+82T\>C variant because RNA was not available.

*PLS3* genotype and expression levels in relation to clinical phenotypes {#s2-6}
------------------------------------------------------------------------

Nineteen nonrelated patients carried 1 of the 5 identified intronic variants in *PLS3* affecting an ESE or ESS. The presence of one of the *PLS3* variants was not associated with a milder or more severe phenotype in these patients compared with patients without a variant (*p* \> 0.05). Six of 27 patients with a discordant phenotype carried an intronic mutation in *PLS3*, but the presence of a mutation did not correlate with a positive or negative discordant phenotype (all mutations *p* adjusted \> 0.05). *PLS3* expression levels did not correlate with clinical severity, e.g., SMA type (*p* = 0.15).

Combined analysis of *PLS3* sequences and PLS3 expression analysis was possible in all siblings of 3 families and 7 nonrelated patients ([figure 2](#F2){ref-type="fig"}). Expression levels of PLS3 were not associated with milder or more severe clinical phenotypes (*p* = 0.53; [figure 2B](#F2){ref-type="fig"}.)

In 1 family, the presence of the c.367+182C\>T variant corresponded with a more severe phenotype or disease course compared with the sibling not carrying the variant (type 2b vs 3a), whereas in another family, the variant was present in the sibling with a milder phenotype (type 2b vs 1c) ([figure 2](#F2){ref-type="fig"}). In the third family carrying this variant, there was no clear effect of the variant. The siblings had SMA type 3a in line with 4 *SMN2* copies, whereas their cousin had a more severe phenotype (type 2a), which corresponded with his 3 *SMN2* copy background. In conclusion, these findings suggest that variability in *PLS3* sequence and RNA expression does not sufficiently explain discordant severity in our patient cohort.

Discussion {#s3}
==========

We performed a hypothesis-based mutational analysis of the candidate disease-modifying genes *PLS3*, *TDP-43, PFN2*, and *FUS* to explore their potential contribution to variability in severity of SMA. We found no evidence for genetic association between variation in these candidate genes and SMA severity, although we identified specific variants in *FUS* and *PLS3* that may be of interest in specific cases. Our findings suggest that other genetic modifiers, both near the *SMN* locus and elsewhere in the genome, are likely to exist that modify SMA disease severity.

Mutations in *FUS* exons 5 and 6 have been reported previously in patients with lower motor neuron diseases.^[@R21],[@R23],[@R25],[@R26]^ More specifically, the p.R216C mutation was previously described in patients with sporadic ALS or patients with essential tremor.^[@R21],[@R24]^ The p.S135N variant has not been described before, and it appears unlikely that this variant is damaging, although the functionality of this particular region of *FUS* is unknown.^[@R25],[@R26]^ FUS and SMN proteins are known to interact and are both involved in RNA processing.^[@R14]^ Of interest, deleterious effects of *FUS* mutations, e.g., dysfunctional axonal growth and branching defects, can be rescued by overexpression of SMN.^[@R14]^ The p.R216C mutation may negatively affect FUS expression or the interaction with SMN and thereby further reduce the functionality of the SMN-FUS complex.^[@R21]^ Partial penetrance of *FUS* mutations has been shown by noncomplete disease segregation in familial ALS.^[@R25]^ However, because the *SMN2* copy number of our patient harboring the p.R216C mutation was in line with the clinical phenotype, the effect of the *FUS* variant cannot at present be further speculated on.

We did not find coding variants in *PFN2* in our cohort of patients. The SMN/PFN2a interaction has been confirmed by previous in vivo studies^[@R27]^ showing alternating levels of PFN2a and SMN to effect SMA phenotype in mice. Previous studies showed that minimal changes in protein levels of either SMN or PFN2 altered their interaction and the downstream RhoA/ROCK pathway and affected neuritogenesis.^[@R27]^ Although we did not find variants in *PFN2*, the fact that heterozygous deletions of *SMN1* with point mutations in exon 5 containing the binding site for profilin^[@R28][@R29][@R32]^ results in an SMA phenotype supports the importance of the SMN/PFN2a interaction. Second, mutations in other profilins (like profilin-1) contribute to the risk of ALS,^[@R19]^ but because of variable penetrance of the mutations,^[@R19],[@R20]^ it is as yet unclear whether such mutations are a direct cause or a risk factor for the development of motor neuron disease.

The modifying effect of PLS3 overexpression on SMA phenotype was first suggested by the finding of high PLS3 expression in lymphoblast cells from peripheral blood in a family with asymptomatic or mildly affected females with a homozygous *SMN1* deletion.^[@R13],[@R33],[@R34]^ Studies in SMA mice and zebrafish supported the role of PLS3 overexpression as shown by the rescue of motor axon defects,^[@R22],[@R35],[@R36]^ improvement of neuromuscular junction alterations,^[@R8],[@R22],[@R35]^ and prolongation of survival.^[@R8],[@R37]^ Other reports showed conflicting results, which may suggest that PLS3 only acts as a modifier in specific families or genetic backgrounds.^[@R10],[@R33],[@R34],[@R38][@R39][@R40]^ We identified 5 intronic variants in *PLS3* that alter splice sites and may thereby modify clinical severity. Because the severity of modifying effects of *PLS3* has been linked to high expression levels, we first studied the relation between these variants and expression, followed by comparison of severity in patients with and without *PLS3* variants. One of the challenges of PLS3 expression analysis is the low expression levels in blood, which has also been reported by other groups.^[@R38],[@R39]^ We used a sensitive droplet digital PCR technique that requires only small amounts of blood to overcome this issue, but we cannot exclude the possibility that even this technique lacks the sensitivity to detect biologically relevant differences in PLS3 expression, at least in blood. An alternative approach, for example, the use of fibroblasts rather than blood was not possible. PLS3 expression levels were higher in patients with intron 3 (c.367+182C\>T) variant, but not in any of the other variants. We have analyzed full-length PLS3 transcripts as described previously,^[@R13]^ although this approach precludes the analysis of correlations between specific mutations and alternative (unknown) isoforms of PLS3 and might therefore have resulted in the lack of correlation between phenotype and expression levels. A further comparison of severity between patients with and without *PLS3* variants did not show a consistent correlation with disease severity, with the notable exception of 1 family, where the intron 3 (c.367+182C\>T) variation coincided with a more severe rather than a milder disease course. This finding is clearly not in line with the presumed protective effect of higher PLS3 expression levels. Combined, our data suggest that specific rare variants in *PLS3* may alter expression levels, but the effect on the clinical phenotype remains unclear.

In the current study, we chose to study a small number of candidate genes in high detail. Because we used targeted next-generation sequencing analysis in our initial screen for variants, we may have missed individual mutational changes that cannot be detected by the designed amplicons. Moreover, genetic variants further up- or downstream of our candidate genes are not included in the current study but may be required to further explain variation in e.g., PLS3 RNA expression. Common variants near modifying genes might affect clinical severity, but were not explored in this study. Whole-genome sequencing approaches might aid in the discovery of other disease-modifying variants, although the identification of predictors for individual patients or small numbers of patients might be complicated by a lack of statistical power that these kind of studies generally require.

The identification and registration of the present (dis)cordant families with multiple affected siblings or first- or second-degree relatives is essential in the identification of possible disease severity modifiers, especially now that such families will become increasingly rare due to the introduction of presymptomatic treatment strategies, prenatal screening, or even preimplantation selection. Larger studies through international collaborative efforts in search for genetic modifiers are needed, especially now that genetic modifiers such as *SMN2* have become potent targets for therapeutic strategies and may help to identify those who benefit most from these intensive therapies.
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